Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus.

MLA

Castagna, Antonella, et al. “Long-Term Efficacy of Dolutegravir in Treatment-Experienced Subjects Failing Therapy with HIV-1 Integrase Strand Inhibitor-Resistant Virus.” Journal of Antimicrobial Chemotherapy (JAC), vol. 73, no. 1, Jan. 2018, pp. 177–82. EBSCOhost, https://doi.org/10.1093/jac/dkx371.

APA

Castagna, A., Ferrara, M., Galli, L., Comi, L., Sterrantino, G., Cenderello, G., Zaccarelli, M., Focá, E., Roncadori, A., Lazzarin, A., Focà, E., & PRESTIGIO Study Group. (2018). Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. Journal of Antimicrobial Chemotherapy (JAC), 73(1), 177–182. https://doi.org/10.1093/jac/dkx371

Chicago

Castagna, Antonella, Micol Ferrara, Laura Galli, Laura Comi, Gaetana Sterrantino, Giovanni Cenderello, Mauro Zaccarelli, et al. 2018. “Long-Term Efficacy of Dolutegravir in Treatment-Experienced Subjects Failing Therapy with HIV-1 Integrase Strand Inhibitor-Resistant Virus.” Journal of Antimicrobial Chemotherapy (JAC) 73 (1): 177–82. doi:10.1093/jac/dkx371.